[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dysautonomia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dysautonomia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,75,103,144,176,264,286],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100624417","non-invasive-vagus-nerve-stimulation-for-chronic-musculoskeletal-pain-100624417",false,"NCT07409363","Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain","A Randomised, Single-blind, Sham-controlled, Crossover Pilot Study Assessing the Effect of Non-invasive Vagus Nerve Stimulation (nVNS) on Autonomic Symptoms and Pain Management in Patients With Chronic Musculoskeletal Pain and Autonomic Dysfunction","RESTORE-MSK","Inclusion Criteria:\n\n1. Individuals diagnosed with musculoskeletal (MSK) conditions and currently experiencing MSK pain lasting for 12 weeks or longer, in line with the ICD-11 criteria for chronic pain.\n2. Identified as having autonomic dysfunction (AD) defined as a score of 17 or more on the Composite Autonomic Symptom Score-31 (COMPASS-31) questionnaire.\n3. Ability to understand and willingness to sign a written informed consent document.\n4. Stated willingness to comply with all study procedures and be available for the duration of the study (approximately 6 weeks).\n5. Ability to read and understand English sufficiently to complete study questionnaires.\n\nExclusion Criteria:\n\n1. Pregnancy (self-reported; safety of nVNS in pregnancy not established).\n2. Advanced heart disease, including: severe heart failure (NYHA Class III-IV), myocardial infarction within the preceding 6 months, or ongoing investigations for cardiac arrhythmias.\n3. Use of an active implantable medical device, including: cardiac pacemaker, implantable cardioverter-defibrillator (ICD), cochlear implant, hearing aid implant, or any other implanted electronic device.\n4. Concurrent use of another electrical stimulation device, including: transcutaneous electrical nerve stimulation (TENS) unit, muscle stimulator, or any other portable electronic stimulation device.\n5. Inability to provide informed consent.","ALL","18 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24],"NA","Chronic musculoskeletal (MSK) pain affects an estimated 20-33% of the global population and is frequently associated with autonomic nervous system dysfunction, characterised by symptoms such as orthostatic intolerance, palpitations, gastrointestinal dysmotility, and fatigue. Conventional treatments often fail to address this autonomic component, limiting their effectiveness. This pilot study investigates whether non-invasive vagus nerve stimulation (nVNS) using the gammaCore Sapphire device can reduce autonomic symptom severity and improve pain in adults with chronic MSK pain and confirmed autonomic dysfunction.\n\nRESTORE-MSK is a randomised, single-blind, sham-controlled, crossover pilot study. Twelve participants with chronic MSK pain (lasting 12 weeks or longer) and autonomic dysfunction (COMPASS-31 score of 17 or more) will be recruited from musculoskeletal clinics at Chapel Allerton Hospital, Leeds. Participants will be randomly allocated to receive either active nVNS or sham stimulation first, followed by a 2-week washout period, then crossover to the alternative treatment. Each treatment period lasts 14 days, with participants self-administering the device twice daily (morning and evening).\n\nThe primary outcome is change in autonomic symptom severity measured by the Composite Autonomic Symptom Score-31 (COMPASS-31). Secondary outcomes include physiological response to the NASA Lean Test, pain severity and interference (Brief Pain Inventory), anxiety and depression (Hospital Anxiety and Depression Scale), quality of life (EQ-5D-5L), intervention acceptability, and recruitment feasibility.\n\nThis pilot study aims to establish feasibility and proof of concept for a larger randomised controlled trial investigating nVNS as a non-pharmacological treatment option for chronic MSK pain with autonomic dysfunction.",[27,28,29],"Chronic Musculoskeletal Pain","Autonomic Dysfunction","Dysautonomia",[31,32,33,34,35,36],"Vagus Nerve Stimulation","Non-invasive Neuromodulation","Chronic Pain","Autonomic Nervous System","GammaCore","COMPASS-31","NOT_YET_RECRUITING","2026-05-06",{"date":40,"type":41},"2026-05-11","ACTUAL",{"date":43,"type":21},"2026-05-14",{"date":45,"type":21},"2026-07-31",{"name":47,"class":48},"University of Leeds","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100470003","blood-pressure-effects-on-cognition-and-brain-blood-flow-in-pd-100470003","NCT05400174","Blood Pressure Effects on Cognition and Brain Blood Flow in PD","Effects of Blood Pressure on Cognition and Cerebral Blood Flow in Parkinson Disease","Inclusion Criteria:\n\n1. Diagnosis of idiopathic Parkinson Disease using the Movement Disorders Society (MDS) Clinical Diagnostic Criteria\n2. Age at least 50 years old\n3. Hoehn \\& Yahr (H\\&Y) stages I-III (early to moderate-stage PD; able to walk without assistance\n4. Proficiency in the English language (native English speaker level)\n\nExclusion Criteria:\n\n1. Any involuntary movements (i.e., tremor or dyskinesia) \\> 3 cm in amplitude (ok if movements are treated with medication), since the motion artifact could interfere with blood pressure monitor data collection\n2. Dementia (including PD dementia)\n3. History of deep brain stimulation (DBS) surgery\n4. Any current unstable, active medical problem, e.g. decompensated heart failure, liver failure, pneumonia, etc.\n5. Moderate or severe carotid artery stenosis (according to North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria\n6. History of cerebral infarction or hemorrhage\n7. Uncontrolled diabetes or any other systemic disease causing autonomic failure\n8. Syncope (fainting) within the past week\n9. Illiteracy (unable to read)\n10. Taking antihypertensive medications or alpha-adrenergic blocking medications, since these can cause hypotension (see \\* below)\n11. Impairment of hearing or vision that is not corrected by devices (e.g., hearing aids or glasses)\n12. Currently pregnant (will be confirmed by women of child-bearing potential with a urine pregnancy test)\n13. Any other condition, which, in the opinion of the investigator, could place the participant at increased risk.\n\n    * Please note that persons may not participate if they are taking any of the following:\n\n      * medications to treat high blood pressure (called \"antihypertensives\") such as clonidine (Catapres), hydralazine, verapamil, diltiazem (Cartia), or medications ending in \"-olol\", \"-artan\", or \"-pril\")\n      * diuretics (also called \"water pills\") such as furosemide (Lasix), bumetanide (Bumex), hydrochlorothiazide (HCTZ; Microzide), or spironolactone (Aldactone)\n      * medications for enlarged prostate such as prazosin (Minipress), terazosin, doxazosin (Cardura), alfuzosin (Uroxatral), or tamsulosin (Flomax)\n\nIf persons are taking these medications and would like to participate in the study, they will be advised to discuss whether they may discontinue these medications for 48 hours before the study visit with their prescribing doctor.","50 Years",{"count":59,"type":21},60,[24],"Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Besides causing symptoms that impair movement, PD also causes non-motor symptoms, such as problems thinking and orthostatic hypotension (OH), i.e., low blood pressure (BP) when standing. About one-third of people with PD have OH, which can cause sudden, temporary symptoms while upright, including lightheadedness, dizziness, and fainting. People with PD and OH can also experience problems thinking that happen only while upright and not while sitting - this can occur without other symptoms, such as feeling dizzy or faint. However, the level of low BP that can affect thinking remains unknown, and no guidelines exist for treating OH when it happens without symptoms. This is significant because OH could be a treatable risk factor for thinking problems in PD, but OH is often not treated if people do not report obvious symptoms.\n\nThis project's goal is to determine how BP affects brain function in PD. The proposed experiments will measure BP and brain blood flow continuously in real-time using innovative wearable technology. Persons with PD with OH and without OH will undergo repeated cognitive tests while supine (lying down) and while upright. I will study the associations between BP, thinking abilities, and brain blood flow, and will compare groups with and without OH. These findings could be important because if a certain level of BP correlates with thinking abilities, then treating OH in PD may prevent thinking problems, which would improve health-related quality of life and reduce disability and healthcare costs.",[63,64,29],"Parkinson Disease","Orthostatic Hypotension","RECRUITING","2026-04-21",{"date":68,"type":41},"2026-04-27",{"date":70,"type":41},"2021-12-14",{"date":72,"type":21},"2026-08-15",{"name":74,"class":48},"University of California, San Diego",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":49},"100442438","data-collection-of-standard-care-of-patients-in-the-emg-section-100442438","NCT05041387","Data Collection of Standard Care of Patients in the EMG Section","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* The patient or the patient's Legally Authorized Representative is capable of informed consent and signs the consent form.\n* Male or female, age 18 and over, no age limit\n* Possible neuromuscular disorder or neurodegenerative disorder.\n\nEXCLUSION CRITERIA:\n\nNo other exclusion criteria for patients","110 Years",{"count":83,"type":21},200,"OBSERVATIONAL","Background:\n\nMost people who are referred to the EMG (Electromyography) Section of the NIH are enrolled into specific active studies. This allows researchers to learn about a range of rare neuromuscular disorders. But study criteria may not give researchers the chance to evaluate a single person or study a common symptom. Therefore, researchers want to assess people with neuromuscular disorders who are not currently enrolled in any NIH studies. They will perform tests on these individuals in the EMG Lab. Then they will create a repository of data that may be used for future research. This will help them learn more about these disorders.\n\nObjective:\n\nTo retain data that is collected as part of participant visits to the NIH.\n\nEligibility:\n\nPeople aged 18 and older who will be visiting the NIH for evaluation of their neuromuscular disorder.\n\nDesign:\n\nParticipants will be screened with a medical record review.\n\nParticipants will have a physical exam. They will be evaluated for their neuromuscular disorder. They may have tests to learn more about how their nerves and muscles work that are called nerve conduction and EMG studies. Their muscles and nerves may be assessed with an ultrasound. Their ability to sweat may be measured. Their heart rate and blood pressure may be taken. Changes to their breathing or changes in their body position may be measured.\n\nParticipant data will be given a unique numerical identifier that can be used if the data is shared. Data will be stored on a server and in a database.\n\nParticipants will have 1-2 visits. Each visit will last less than 4 hours. They may be contacted for a follow-up visit.",[87,88,29],"Neuropathy","Muscle Disorders",[90,91,92],"Standard of Care","Screening","NEUROMUSCULAR DISORDERS","2026-03-07",{"date":95,"type":41},"2026-03-10",{"date":97,"type":41},"2024-06-24",{"date":99,"type":21},"2031-05-01",{"name":101,"class":102},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":128,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":49},"100521768","phase-2-personalized-brain-stimulation-to-treat-chronic-concussive-symptoms-100521768","NCT06073886","Personalized Brain Stimulation to Treat Chronic Concussive Symptoms","Personalized Circuit-Based Frontoamygdala Neuromodulation for Persistent Post-Concussive Symptoms","Inclusion Criteria:\n\n* Mild traumatic brain injury (mTBI) defined in accord with the World Health Organization criteria in the last 12 months\n* age 18-65 at the time of the mTBI\n* high burden of post-concussive symptoms defined as a score \\>=20 on the Rivermead Post-Concussion Symptoms Questionnaire\n\nExclusion Criteria:\n\n* objective neurologic deficits\n* ongoing or prolonged (\\>3 months) post-concussive symptoms from a prior mTBI within 2 years of the index injury\n* history of transcranial magnetic stimulation (TMS) therapy\n* contraindications for TMS or magnetic resonance imaging (MRI) (e.g., metallic implant other than dental, pacemaker)\n* severe mental, physical, or medical problems that would impede participation or pose a risk for the planned intervention (e.g., liver, kidney, or heart disease, uncontrolled diabetes or hypertension, malignancy, psychosis, previous seizure, pregnancy)\n* active alcohol or illicit drug abuse\n* inability to speak and read English","65 Years",{"count":112,"type":21},75,[114],"PHASE2","The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury. These symptoms can interfere with daily functioning, causing difficulty returning to physical activity, work, or school. Previous concussion therapies have not been personalized nor involved direct treatments to the brain itself. The treatment being tested in the present study is a noninvasive, personalized form of brain stimulation, called transcranial magnetic stimulation (TMS).\n\nThe investigators intend to answer the questions:\n\n1. Does personalized TMS improve brain connectivity after concussion?\n2. Does personalized TMS improve avoidance behaviors and chronic concussive symptoms?\n3. Do the improvements last up to 2 months post-treatment?\n4. Are there predictors of treatment response, or who might respond the best?\n\nParticipants will undergo 14 total visits to University of California Los Angeles (UCLA):\n\n1. One for the baseline symptom assessments and magnetic resonance imaging (MRI)\n2. Ten for TMS administration\n3. Three for post-treatment symptom assessments and MRIs\n\nParticipants will have a 66% chance of being assigned to an active TMS group and 33% chance of being assigned to a sham, or inactive, TMS group. The difference is that the active TMS is more likely to cause functional changes in the brain than the inactive TMS.",[117,118,119,120,121,122,123,29,124,125,126,127],"Post-Concussion Syndrome","Concussion, Brain","Mild Traumatic Brain Injury","Head Injury","Headache","Dizziness","Cognitive Symptom","Anxiety","Irritability; Syndrome","Depression","Post-traumatic Stress Disorder",[129,130,131,132,133,134],"Transcranial Magnetic Stimulation","Magnetic Resonance Imaging","Functional MRI","Personalized neuromodulation","Amygdala","Prefrontal Cortex","2026-02-21",{"date":137,"type":41},"2026-02-24",{"date":139,"type":41},"2024-03-06",{"date":141,"type":21},"2027-01",{"name":143,"class":48},"University of California, Los Angeles",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":151,"sex":152,"minAge":153,"maxAge":18,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":49},"100582430","autonomic-reactivity-and-personalized-neurostimulation-100582430","NCT06863207","Autonomic Reactivity and Personalized Neurostimulation","Autonomic Reactivity to Restore a Dysregulated Brain-Gut Axis Via Targeted Therapy","Inclusion Criteria:\n\n* 11 to 18 years of age\n* English speaking\n* meeting Rome IV diagnostic criteria for cyclic vomiting syndrome or functional dyspepsia and willingness to participate and consent\u002Fassent to the study\n* All subjects will have a constellation of chronic symptoms indicative of autonomic dysfunction for minimum 3 months: postural dizziness\u002Flightheadedness, syncope, palpitations, fatigue, sleep disturbance, thermoregulatory abnormalities and cognitive impairment with upright position +\u002F- abnormal autonomic testing if performed per standard of care as per American Autonomic Society consensus criteria.\n\nExclusion Criteria:\n\n* Presence of organic disease that may explain symptoms\n* Requirement for parenteral nutrition\n* Developmental delays precluding accurate symptom report\n* Severe dermatological condition or active infection of external or middle ear\n* Implanted electrical device\n* Severe mental health disorder not controlled by therapy (schizophrenia, bipolar disease, severe depression, post-traumatic distress disorder) and\u002For psychotic features which could influence symptom report or ANS measurements and result in adverse reactions to hypnosis therapy",true,"FEMALE","11 Years",{"count":155,"type":21},120,[24],"Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsia, irritable bowel) rather than underlying pathophysiology. Many patients manifest comorbidities suggesting an underlying autonomic nervous system (ANS) dysregulation (palpitations, dizziness, cognitive dysfunction). Unfortunately, due to common features of anxiety and visceral hyperreactivity and lack of obvious pathology, children with DGBI are frequently diagnosed with psychosomatic or 'benign, functional disorders' and treated with empiric antidepressants despite lack of scientific support and risks of serious side effects. Little is known about the underlying brain-gut mechanisms linking these comorbidities. A lack of targeted treatment options naturally follows the paucity of mechanistic data. A dysregulated ANS response circuit via brainstem nuclei is linked to visceral hypersensitivity. As the team's prior research has shown, ANS regulation can be non-invasively measured via several validated indices of cardiac vagal tone. Using the novel vagal efficiency (VE) metric, the investigators have demonstrated inefficient vagal regulation in cyclic vomiting syndrome and pain-related DGBI and that low VE predicts response to non-invasive, auricular percutaneous electrical nerve field stimulation (PENFS) therapy. PENFS targets brainstem vagal afferent pathways and, along with brain-gut interventions such as hypnotherapy, are the only therapies currently proven effective for pediatric DGBI. Individualizing neurostimulation based on sensory thresholds while assessing dynamic ANS reactivity offers a path towards personalized medicine using the most effective therapies to date. This proposal will test the feasibility of an ANS tracking software in assessing real-time, autonomic regulation and providing individualized neurostimulation in children with nausea\u002Fvomiting and ANS imbalance.",[159,160,161,29],"Functional Gastrointestinal Disorders (FGIDs)","Cyclic Vomiting Syndrome","Functional Dyspepsia",[163,164,165,166],"autonomic dysfunction","auricular neurostimulation","gastric motor function","gut-directed hypnotherapy","2026-02-11",{"date":169,"type":41},"2026-02-13",{"date":171,"type":41},"2025-01-24",{"date":173,"type":21},"2029-06",{"name":175,"class":48},"Medical College of Wisconsin",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":151,"sex":17,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":186,"studyType":84,"phases":4,"briefSummary":187,"conditions":188,"keywords":232,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":49},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform","2 Years",{"count":185,"type":21},10000,"10 Years","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[189,190,191,192,193,194,195,196,197,198,199,200,29,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[208,233,234,235,236,237,238,239,240,241,190,242,243,244,245,246,210,247,248,249,250,251,252,253,254],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","2026-01-20",{"date":257,"type":41},"2026-01-22",{"date":259,"type":41},"2023-07-05",{"date":261,"type":21},"2030-12-31",{"name":263,"class":48},"Brain Inflammation Collaborative",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":49},"100496198","the-long-covid-19-wearable-device-study-100496198","NCT05741112","The Long COVID-19 Wearable Device Study","Inclusion Criteria:\n\n* Is at least 18 years old.\n* Has a self\u002Fand or physician diagnosis of:\n* Long COVID (based on the WHO working definition),\n* ME\u002FCFS (myalgic encephalomyelitis \u002F chronic fatigue syndrome, self-diagnosis based on IOM criteria), and\u002For\n* POTS (Postural Orthostatic Tachycardia Syndrome).\n* Is interested in tools to manage ME\u002FCFS, POTS, and\u002For Long COVID symptoms.\n* Owns a wearable device they are willing to use for this study or does not own a device and agrees to utilize a study-provided one.\n* Agrees to wear the device throughout the study period, share the data with the study, and sync data at least weekly.\n* Has access to a smartphone or tablet to enable syncing wearable data and viewing device feedback.\n* Agrees to disclose involvement in other ME\u002FCFS, POTS, and\u002For Long COVID interventions such as medical treatment, self-management, and other interventional studies.\n* Agrees to complete at least 75% of the study surveys.\n\nExclusion Criteria:\n\n* As long as they meet inclusion there is no exclusion",{"count":271,"type":21},100500,[24],"To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.",[208,275,29,233,234,276],"Postural Orthostatic Tachycardia Syndrome","Long Covid19","2025-05-09",{"date":279,"type":41},"2025-05-11",{"date":281,"type":41},"2023-11-16",{"date":283,"type":21},"2025-12-01",{"name":285,"class":48},"Scripps Translational Science Institute",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":151,"sex":17,"minAge":294,"maxAge":110,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":49},"100558723","effects-of-osteopathic-technique-on-autonomic-nervous-system-activity-100558723","NCT06554834","Effects of Osteopathic Technique on Autonomic Nervous System Activity","Effects of Three Therapeutic Sessions of the Fourth Ventricle Compression Technique and Rib Raising Osteopathic Technique on Autonomic Nervous System Activity Measured by Heart Rate Variability in 109 Healthy Individuals","Osteo","Inclusion Criteria:\n\n* Age between 20 and 60 years.\n* Subjects not currently undergoing any form of rehabilitation, physiotherapy, or osteopathy\n\nExclusion Criteria:\n\n* Unstable arrhythmia in the patient's history and symptoms related to chest organs (retrosternal pain, difficulty breathing).\n* Pregnancy.\n* Menstruation.\n* Smoking.\n* Symptoms suggestive of disorders related to bowel obstruction (bloating with pain, vomiting, diarrhea).\n* Surgical treatment in the head.\n* Neurological diseases.\n* Back and peripheral joint pain, trauma, and musculoskeletal dysfunction in the last 12 months.\n* Having undergone physiotherapy or osteopathy treatment within the last month, regardless of the reason","20 Years",{"count":296,"type":21},109,[24],"Cranial osteopathic manipulation technique for brain and cranial nerve function, known as the fourth ventricle compression (CV4), has been recognized. Rib raising (RR), aimed at reducing rib restriction and conditions associated with sympathetic hypertonia, is also employed. This study aimed to assess, in about 109 healthy individuals, the effects of osteopathic techniques (CV4 and RR) on autonomic nervous system (ANS) activity, as measured by heart rate variability (HRV).",[300,29],"Healthy",[34,302,303],"Osteopathic Medicine","Heart Rate Variability","2024-08-14",{"date":306,"type":41},"2024-08-16",{"date":308,"type":41},"2024-06-20",{"date":310,"type":21},"2024-11-10",{"name":312,"class":48},"SomaticMed"]